Indicaciones y contraindicaciones oncológicas del uso de hormonas en la menopausia

José Antonio Sarriá

doi:10.31053/1853.0605.v62.n2.27917

Authors

José Antonio Sarriá

DOI:

https://doi.org/10.31053/1853.0605.v62.n2.27917

Keywords:

.

Abstract

The lile expectation has been changeable the manner of menopause handling.At the saine time,the women after fifty have the highest incidence of cancer. The hormonal replacement therapy (HT) tu date have very few indication for patients with cancer. The oncologic contraindication for 1-IT are analysed in detail,particulary for breast tumor. At the present tirne,the studies and the metanalysis oii HT and hreat cancer ilot showed a quantitative increase on the risk. We are looking for selective hormone with antagonist for enclornetrium and breast receptors, and effectiveness oil the others areas.

Downloads

Download data is not yet available.

References

Pickard JH,Yeh I,Weeler JE et al Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone Fertility and Sterility 2001,76:25

Scarabin PY,Oger E, Plu-Bureau G D Differential association of oral and transdermal estrogen replacement therapy with venous thromboembolism risk Lancet 2003,362:428

Pike MC,Peters RK,Cozen W,et al Estrogen-progestin replacement therapy and endometrial cancer.J Nati Cancer Inst. 1997,89:1110

Giordano S,diRienzo MF,Olivero M,et al The c-metIHGF receptor in human tumor European J Cancer Prev. 1992,1(suppl) 45:9

Marconcini L,Marchio S, Morbidelli L, et al C-fos induced growth factor/ vascular endotelial factor D induces angiogenesis. Proc. Natl Acad. Sci USA 1999,96:9671

McCawley LJ,Matrisian LM Matriz metal lo - pro te i nasa mu it i funcional contributor to tumor progresión. Mol.Med Today 2000,6:149

Morin MJ,From oncogene todrug:develoment of small molecule tyrosine kinase inhibitors as antitumor and antiangiogenesis agents. Oncog. 2000, 19:6574

Oreen PK,Weiss NS, McKnight B et al Risk of endometrial cancer following cessation of menopausal hormone use.Cancer Cause Control 1996,7:575

Sturdee DW,Ulrch LG, Barlow DH, et al The endometrial response to sequential and continuous combined estrogen progestogen replacement therapy. Br J Obstet Gynaecol. 2000,107:1392

Wells M, Ulrich LO, Sturdee DW, et al Effect on endometrium of long term treatment with continuous combined estrogen-progestogen replacement therapy Br J. Br. Med, Journal 2002.325:239

Anderson GL, Judd HL, KaunitzAM, et al Effects of estrogen plus progestin on gynaecologic cancers and associated diagnosis procedures.JAMA 2003,290:1739

Hempling Wong C,Piver MS et al Hormone replacement therapy as a risk factor for epithelial ovarian cancer:results of a case control study. Obstet,Gyn 1997,89:1012

Garg RKerlikwski K,Subak L,et al Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a metanalysis. Obstet.Gynecol 1998,92:472

Riman T,Dickman RNilsson S, et al Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J. Natl. C. Inst 2002, 94:497

Roussow JE,Andersson GL,Prentice RL,et al Risk and benefits of estrogen plus progestin in healthy posmenopausal women.JAMA 2002,288:321

Lacey JV,Mink P,Lubin JH,et al Menopausal hormone replacement therapy and risk of ovarian cancer JAMA 2002,288:334

Rodríguez C,Patel AV,Calle EE, et al Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women JAMA2001,285: 1460

Collaborative Group on Hormonal factors in Breast Cancer.- Breast Cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet

1997,350:1047

Clemons M,Gross P Estrogen and de risk of breast cancer. New England J.Med. 2001, 344:276

Bush TL,Whiteman M,Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001,98:498

Ross WK.Paganini Hill A,Wan PC, et al Effect of hormone replacement therapy on breast cancer:estrogen vsestrogen plus progestin. J.Natl Cancer Inst.2000,92:328

Steimberg KK,Thacker SB,Smith SJ, et al.A metanalysis of the effect of estrogen replacement therapy on the risk of breast cancer JAMA 1991,265:1985

Schaírer C,Lubin J,Troisi R, et el Menopausal estrogen and estrogen/ progestin replacement therapy and breast cancer risk JAMA 2000.283:485

Huang Z,Hankison SEWColditz GA etaIJAMA 1997,278:1407

Millon Women Study Collaborators.Breast cancer and hormone replacement therapy in the millon women study Lancet 2003,362:419

DiSaia PJ,BrewsterWR,Ziogas A et al Breast cancer survival and hormone replacement therapy: a cohort análisis AmJ,Clin Oncol.2000,23:54 1

Bush TL,Whiteman M,Flaws JAHormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol .2001,98:498

O'Meara ES,Rossing MA,Daling JR et al Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality Journal National Cancer Institute 2001,93:754

Batur P,Blixen CE,Moore HC, et al Menopausal hormone therapy in patients with breast cancer. Cleveland Clinic,Nams, 14th meeting Set.2003,P 49

Women's Health Iniciative- Effects of conjuget equine estrogen in postmenopausal women with hyterectomie. JAMA 2004,291:1701

Sandier RS, Halabi S, Baron JA et al.A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New Engl J Med 2003,348:1939

Grodstein F,Newcomb PA, Stampfer MJ —Postmenopausal hormone therapy and the risk of colorectal cancer:a review and metanalysis Am.J Med. 1999,106:574

Winawer S,Fletcher R,Rex D et al- Colorectal cancer screening and survillance clinical guide unes and rationale:update based on new evidence. Gastroenterology 2003,124:544

Chlebowsky RT,Wactuwski-Wende J,Ritenbaugh Ch,et al. Estrogen plus progestin and in colorectal cancer in postmenopausal women. N.Engl.J Med 2004,350:991